TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Maximum Flow Rate (Qmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Urinary outcomes
Primary endpoint: Eradication of Staphylococcus Aureus Carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Plasma Levels of L-arginine and L-citrulline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of L-citrulline in Preterm Infants: Measured by at Least One Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With an Increase Plasma Level of L-citrulline > 37 Micromol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: No. of women receiving oxytocin stimulation during Labour
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sensitivity and specificity of Ariosa Harmony™ Prenatal Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Proportion of children diagnosed with active TB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: modified Rankin score (mRS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Infant behavior and development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: International Index of Erectile Function-Erectile Dysfunction (IIEF-ED) Domain Score
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Impact on the Health of the Patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Efficacy
Endpoint domain: Physiological/clinical
Primary endpoint: Change in preoperative anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Health status assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Early response to ITP treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Permeability changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration (AUC) versus time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of MK1809
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reported With Each Solicited Local Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reported With Each Solicited General Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reported With Any Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of hydroxyurea therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of hydroxyurea therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gradings of oral mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline on depressed mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Pain Score on Daily Pain Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Thrombosis Generation (MTG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rates of injection-site and systemic reactions post Tdap administration
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of preterm and small for gestational age (SGA) births
Endpoint domain: Mortality/survival
Primary endpoint: Identification of SCC and BCC areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Identification of actinic keratoses areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 2 year progression free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Solicited Local Adverse Events for 7 Days After First Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Solicited Local Adverse Events for 7 Days After Second Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Solicited Systemic Adverse Events for 7 Days After First Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Solicited Systemic Adverse Events for 7 Days After Second Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Unsolicited Adverse Events for 28 Days After First Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Union Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hardware Failures
Endpoint domain: Adverse events/effects
Primary endpoint: Acoustic measures of voice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Objective Sleep Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sleep Efficiency as Assessed by Actigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Subjective Sleep Quality as Assessed by the Pittsburgh Sleep Quality Index (PSQI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of VAS Pain Scores for the First 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cosmetic Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: decrease blood loss during hysterectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Major Cardiovascular Events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systolic Blood Pressure After 4 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic Blood Pressure After 4 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immunological effects on nasal mucosal tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Variability of kinematic simplified functional score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison to histology for positive or suspicious cystoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Metabolic Response (CMR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Standard Uptake Ratio (SUR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary Cortisol (SC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on State-Trait Anxiety Inventory (STAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: total dose of intravenous PCA morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: pain intensity reports
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency and type of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: blood and urine levels of morphine and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nasal Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent recovery of salivary gland function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of proinflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of hyaluronic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of type 1 collagen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of type 3 collagen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 36-Item Short-Form Health Survey (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Peak and Trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy of Matrifen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5 years bladder preservation rate
Endpoint domain: Mortality/survival
Primary endpoint: Criminal Activities in Past 30 Days
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Any Substance Use Past 30 Days
Endpoint domain: Adverse events/effects
Primary endpoint: Change in size of lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction of surgical activity for thyroid disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ALSFRS-R score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: invasive ventilator or death
Endpoint domain: Mortality/survival
Primary endpoint: Percent Change in Tumor Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of subjects reaching responder status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Contrast-induced Nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Development of a new biomarker for diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of Nintedanib in Plasma (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of Nintedanib in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Well-Being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Best corrected high contrast distance visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: optimal imaging protocol for heart structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Eye Dryness Score (7-Day Average)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Corneal Fluorescein Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Routes and rates of excretion of TKI258 and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and Tolerability of TKI258
Endpoint domain: Adverse events/effects
Primary endpoint: Overall improvement of skin laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in symptom intensity of acrophobia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI sensitivity for detection of pulmonary nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of cancer cells in biopsy samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Western Aphasia Battery (WAB-R) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Engraftment of low sulfate reducing microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in toxicity profile of chemotherapy treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Renal transplant rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Organ loss
Endpoint domain: Mortality/survival
Primary endpoint: Maximal Tolerated Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with specific paradoxical Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Binge Eating Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Mass Index (Percent Weight Loss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Ulcer Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and intensity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Reductions in Alcohol Consumption
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 6 Minutes Walk Distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Self-monitoring and self-control scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Level of decisional conflict
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Final post-PCI FFR result ≥0.90
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cough remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline in Eczema Area and Severity Index (EASI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in the ADHD-Rating Scale (ADHD-RS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Clinical Global Impression - Severity (CGI-S)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Geometric Mean Titer of Serum Neutralizing Antibody Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fasting Plasma Nitrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting Plasma Nitrite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 90 minute plasma Nitrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 90 minute plasma Nitrite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change In Area Under The Plasma Concentration Versus Time Curve (AUC) For Active α-Galactosidase A (α-Gal A) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change In Maximum Observed Plasma Concentration (Cmax) For Active α-Gal A Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change In Time To Maximum Observed Plasma Concentration (Tmax) And Terminal Elimination Half-life (T1/2) For Active α-Gal A Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of capillary blood lactate measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in HIV Testing Behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Confirmed Hypoglycaemic Episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Nocturnal Confirmed Hypoglycaemic Episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Change in total physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SUVmax on 18F-DCFPyL PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Asthma Exacerbation
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC) Extrapolated to Infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Cytisine Excreted in Urine Over 48 Hours (Ae0-48h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Total Cytisine Excreted in Urine Over 48 Hours (Ae0-48h%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Conventional Attack Treatment Use Within 12 Hours of Study Drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital Status at Hospital Discharge
Endpoint domain: Mortality/survival
Primary endpoint: Presence of specific genetic markers associated with hemorrhagic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection Site and Systemic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: DAS-28 criteria evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications assessment
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of treatment emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Health Satisfaction SF-12
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gait Profile Score (GPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects registered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Baseline-adjusted area under the serum epoetin concentration curve (AUC0-48)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum serum epoetin concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from time of dose administration to the time of the last measurable concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Passive glenohumeral abduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type of resistant microorganisms in intestinal and nasal flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Negative Predictive Value of Complete Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain intensity measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in functional disability measurement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient Ability to Prepare and Administer the 13C-Spirulina GEBT
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Patient Ability to Complete the GEBT Test Request Form
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Safety of Telehealth Administration of 13C-Spirulina GEBT
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of stent strut malapposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of stent strut tissue coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Failing to Meet Safety Endpoint Related to Maraviroc for Dose-Finding
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Failing to Meet Safety Endpoint Related to Maraviroc for Analysis
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Failing to Meet PK Target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak oxygen consumption (VO2-peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in brain activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Differences in catheter biofilm microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of Responders at Day 29 in the ILA of Glabellar Lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to first bowel movement after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Need for magnesium citrate or enemas in the immediate post-operative period
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Calcification change of Aortic valve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Atorvastatin and Fenofibric acid AUCτ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Atorvastatin and Fenofibric acid Css,max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reaction Time on the N-back Cognitive Test (0-back Condition)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reaction Time on the N-back Cognitive Test (1-back Condition)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: score of the Montgomery-Asberg Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in transcutaneous bilirubin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of patients with behavioral risks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Survival of the reconstructions
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Participants With at Least One Serious Infection Through Week 24
Endpoint domain: Adverse events/effects